Your browser doesn't support javascript.
loading
Brolucizumab tras fracaso de aflibercept con terapia fotodinámica en vasculopatía coroidea polipoidea: reporte de un caso / Brolucizumab after failure of aflibercept with photodynamic therapy in polypoidal choroidal vasculopathy: A case report
Yuan, P. H; Khan, H. M; Sumita, F. A. G; Ribeiro Monteiro, M. L; Preti, R. C; Navajas, E. V.
Affiliation
  • Yuan, P. H; University of British Columbi. Faculty of Medicine. Vancouver. Canadá
  • Khan, H. M; University of British Columbi. Faculty of Medicine. Vancouver. Canadá
  • Sumita, F. A. G; University of British Columbi. Department of Ophthalmology and Visual Sciences. Vancouver. Canadá
  • Ribeiro Monteiro, M. L; University of São Paulo Medical School. Division of Ophthalmology. São Paulo. Brasil
  • Preti, R. C; University of São Paulo Medical School. Division of Ophthalmology. São Paulo. Brasil
  • Navajas, E. V; University of British Columbi. Department of Ophthalmology and Visual Sciences. Vancouver. Canadá
Arch. Soc. Esp. Oftalmol ; 98(12): 713-717, dic. 2023. ilus
Article in Spanish | IBECS | ID: ibc-228146
Responsible library: ES1.1
Localization: ES15.1 - BNCS
RESUMEN
Describimos un caso de vasculopatía coroidea polipoidea con líquido subretiniano persistente a pesar de múltiples tratamientos intravítreos con bevacizumab, ranibizumab y aflibercept, así como aflibercept asociado a terapia fotodinámica. El paciente alcanzó la resolución completa después de la inyección intravítrea de brolucizumab, pero experimentó una recurrencia del líquido subretiniano 12 semanas después de la suspensión. Brolucizumab podría ser una opción para tratar el líquido subretiniano después del fracaso de otros agentes anti-VEGF asociados con la terapia fotodinámica. (AU)
ABSTRACT
We describe one case of polypoidal choroidal vasculopathy with persistent subretinal fluid despite multiple treatment with intravitreal bevacizumab, ranibizumab and aflibercept, as well as aflibercept associated with photodynamic therapy. The patient reached complete resolution after intravitreal brolucizumab injection, but experienced recurrence of subretinal fluid 12 weeks after discontinuation. Brolucizumab might be an option in treating subretinal fluid after failure of other anti-VEGF agents associated with photodynamic therapy. (AU)
Subject(s)

Search on Google
Add to My VHL
Print
XML

Collection: National databases / Spain Database: IBECS Main subject: Photochemotherapy / Antibodies, Monoclonal, Humanized Limits: Female / Humans Language: Spanish Journal: Arch. Soc. Esp. Oftalmol Year: 2023 Document type: Article Institution/Affiliation country: University of British Columbi/Canadá / University of São Paulo Medical School/Brasil
Search on Google
Add to My VHL
Print
XML

Collection: National databases / Spain Database: IBECS Main subject: Photochemotherapy / Antibodies, Monoclonal, Humanized Limits: Female / Humans Language: Spanish Journal: Arch. Soc. Esp. Oftalmol Year: 2023 Document type: Article Institution/Affiliation country: University of British Columbi/Canadá / University of São Paulo Medical School/Brasil